EPS for EyeGate Pharmaceuticals, Inc. (EYEG) Expected At $-0.23; Hubbell (HUBB) SI Increased By 53.06%

May 8, 2018 - By Vivian Park

Hubbell Incorporated (NYSE:HUBB) Logo

Hubbell Inc (NYSE:HUBB) had an increase of 53.06% in short interest. HUBB’s SI was 1.24 million shares in May as released by FINRA. Its up 53.06% from 810,100 shares previously. With 425,200 avg volume, 3 days are for Hubbell Inc (NYSE:HUBB)’s short sellers to cover HUBB’s short positions. The SI to Hubbell Inc’s float is 2.4%. The stock increased 0.76% or $0.79 during the last trading session, reaching $104.76. About 399,106 shares traded. Hubbell Incorporated (NYSE:HUBB) has risen 1.85% since May 8, 2017 and is uptrending. It has underperformed by 9.70% the S&P500.

Analysts expect EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.23 EPS on May, 14.They anticipate $0.05 EPS change or 17.86% from last quarter’s $-0.28 EPS. After having $-0.21 EPS previously, EyeGate Pharmaceuticals, Inc.’s analysts see 9.52% EPS growth. The stock increased 0.76% or $0.0036 during the last trading session, reaching $0.478. About 285,069 shares traded. EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 82.90% since May 8, 2017 and is downtrending. It has underperformed by 94.45% the S&P500.

Among 6 analysts covering Hubbell Inc (NYSE:HUBB), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Hubbell Inc had 14 analyst reports since October 23, 2015 according to SRatingsIntel. On Tuesday, December 20 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm has “Neutral” rating given on Monday, March 7 by JP Morgan. The stock has “Overweight” rating by Morgan Stanley on Monday, October 2. The stock of Hubbell Incorporated (NYSE:HUBB) has “Overweight” rating given on Thursday, January 18 by JP Morgan. The rating was downgraded by JP Morgan on Thursday, January 7 to “Neutral”. The rating was initiated by JMP Securities with “Mkt Perform” on Monday, June 19. The stock of Hubbell Incorporated (NYSE:HUBB) has “Neutral” rating given on Friday, May 13 by Barrington Research.

Hubbell Incorporated designs, manufactures, and sells electrical and electronic products in the United States and internationally. The company has market cap of $5.75 billion. It operates through two divisions, Electrical and Power. It has a 23.86 P/E ratio. The Electrical segment offers standard and special application wiring device products, rough-in electrical products, connector and grounding products, lighting fixtures and controls, and other electrical equipment for use in industrial, commercial, and institutional facilities by electrical contractors, maintenance personnel, electricians, utilities, and telecommunications companies, as well as components and assemblies for the natural gas distribution market.

More news for Hubbell Incorporated (NYSE:HUBB) were recently published by: Seekingalpha.com, which released: “Hubbell Inc. 2018 Q1 – Results – Earnings Call Slides” on April 24, 2018. Seekingalpha.com‘s article titled: “Hubbell’s (HUBB) CEO David Nord on Q1 2018 Results – Earnings Call Transcript” and published on April 24, 2018 is yet another important article.

Among 2 analysts covering Eyegate Pharmaceuticals (NASDAQ:EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharmaceuticals had 2 analyst reports since November 12, 2015 according to SRatingsIntel. On Thursday, November 12 the stock rating was initiated by Maxim Group with “Buy”. On Wednesday, December 23 the stock rating was initiated by Chardan Capital Markets with “Buy”.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $15.29 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More recent EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: Globenewswire.com which released: “EyeGate Announces $11.25 Million Public Offering” on April 13, 2018. Also Globenewswire.com published the news titled: “EyeGate Issued New Patent for Iontophoretic Contact Lens Technology” on April 11, 2018. Streetinsider.com‘s news article titled: “Eyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage Gel” with publication date: April 09, 2018 was also an interesting one.

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>